Actimed Plans to Advance Treatment for Muscle Wasting in ALS

Actimed Plans to Advance Treatment for Muscle Wasting in ALS

292192

Actimed Plans to Advance Treatment for Muscle Wasting in ALS

Actimed Therapeutics is developing S-oxprenolol to prevent muscle wasting and body mass loss due to amyotrophic lateral sclerosis (ALS), using proceeds from a recent license agreement with Faraday Pharmaceuticals. Under the agreement, Faraday acquired global rights to develop and commercialize S-oxprenolol for muscle-affecting disorders other than ALS, particularly cancer-related cachexia, a wasting syndrome. Actimed received an upfront payment of $550,000, and is eligible for a $2.7 million near-term milestone payment, plus additional revenue as more milestones are…

You must be logged in to read/download the full post.